[CA 125, CA 19.9, MCA, CEA, 17 beta-estradiol and progesterone in functional and benign cysts and carcinoma of the ovary].
CA 125, CA 19.9, CEA, MCA, E2 and P levels have been assessed in the serum and in the ovarian mass fluid of 216 patients through echo-guided puncture to distinguish between functional, benign and malignant cystic neoplasm. Statistically evaluated data have been assessed through histological diagnosis in 122 cases: cyst fluid markers do not always differentiate ovarian carcinoma from benign cysts, while they have a significant concentration in persistent functional cysts (follicular and luteal) if compared with benign and malignant neoplasms. The following management is suggested: 1) Echo-guided puncture in case of simple, persistent ovarian cyst with low levels of CA 125 and CA 19.9 in serum; 2) Operation in case of fatty, chocolate or mucinous fluid. Wait and see if the fluid is either clear or hematic/chocolate with high P levels (luteal cyst); 3) Operation on simple cyst with high CA 125 ald low E2 and P levels (serous c.), in case of relapse or persistence after aspiration; 4) Wait and see if CA 125 is low and E2 and P levels are high (follicular c.).
Caione
C
C
Divisione di Ostetricia e Ginecologia, Ospedale Carlo Poma, Mantova.
Minelli
L
L
Angiolillo
M
M
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D001707:Biopsy, Needle / Q000295:instrumentation / Q000379:methods; D018394:CA-125 Antigen / Q000032:analysis; D018395:CA-19-9 Antigen / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002277:Carcinoma / Q000737:chemistry* / Q000453:epidemiology / Q000473:pathology; D016001:Confidence Intervals; D003937:Diagnosis, Differential; D004958:Estradiol / Q000032:analysis; D005260:Female; D006801:Humans; D010048:Ovarian Cysts / Q000737:chemistry* / Q000453:epidemiology / Q000473:pathology; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000453:epidemiology / Q000473:pathology; D010053:Ovary / Q000000981:diagnostic imaging / Q000473:pathology; D011374:Progesterone / Q000032:analysis; D018084:Ultrasonography, Interventional / Q000295:instrumentation / Q000379:methods
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; C057387:mucinous carcinoma-associated antigen; D011374:Progesterone; D004958:Estradiol
CA 125, CA 19.9, MCA, CEA, 17 beta-estradiolo e progesterone nelle cisti funzionali e benigne e nel carcinoma dell'ovaio.